Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)’s share price was up 0% during trading on Tuesday . The stock traded as high as $24.55 and last traded at $23.62. Approximately 788,782 shares were traded during trading, a decline of 28% from the average daily volume of 1,090,230 shares. The stock had previously closed at $23.61.
Several equities analysts have recently commented on ADMS shares. JMP Securities reaffirmed an “outperform” rating and set a $33.00 target price (up from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Zacks Investment Research lowered Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, August 11th. BidaskClub raised Adamas Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, August 23rd. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Finally, Piper Jaffray Companies reiterated an “overweight” rating and set a $30.00 price objective on shares of Adamas Pharmaceuticals in a research report on Friday, September 1st. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $39.50.
The stock has a 50-day moving average of $20.66 and a 200 day moving average of $17.95. The firm’s market capitalization is $555.20 million.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.81) by ($0.12). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.03 million. The company’s quarterly revenue was down 90.9% on a year-over-year basis. During the same period last year, the firm posted ($0.78) earnings per share. Analysts anticipate that Adamas Pharmaceuticals, Inc. will post ($3.77) EPS for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Tower Research Capital LLC TRC acquired a new stake in shares of Adamas Pharmaceuticals during the second quarter worth approximately $109,000. American International Group Inc. increased its holdings in shares of Adamas Pharmaceuticals by 7.1% during the first quarter. American International Group Inc. now owns 10,284 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 682 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Adamas Pharmaceuticals during the second quarter worth approximately $184,000. Wells Fargo & Company MN increased its holdings in shares of Adamas Pharmaceuticals by 28.4% during the first quarter. Wells Fargo & Company MN now owns 15,166 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 3,358 shares in the last quarter. Finally, Alps Advisors Inc. increased its holdings in shares of Adamas Pharmaceuticals by 6.7% during the second quarter. Alps Advisors Inc. now owns 20,182 shares of the specialty pharmaceutical company’s stock worth $353,000 after buying an additional 1,272 shares in the last quarter. 71.95% of the stock is owned by institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.com-unik.info/2017/10/31/adamas-pharmaceuticals-inc-adms-trading-up-0.html.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
What are top analysts saying about Adamas Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Adamas Pharmaceuticals Inc. and related companies.